• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·BACPHAR.BO
Share

Bacil Pharma Limited Stocks

₹ 21.09Last Updated 21.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 3.24M

₹ 21.09
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bacil Pharma Limited operates as a specialist in the production and distribution of a diverse range of pharmaceutical, therapeutic, and botanical goods. Their primary manufacturing facility, situated in Lote-Parshuram, is additionally equipped for the processing of herbal extracts and the synthesis of drug intermediates. The company was established on May 8, 1987, and its corporate headquarters are located in Mumbai, India.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 18:52

The sell-off in U.S. stocks continued: The Nasdaq fell nearly 2%. What should investors do?

22.10.2026 18:02

"Demand Is Through the Roof": Huang Identified Obstacles to Neocloud's Growth Amid Its Sell-Off

22.10.2026 17:35

An expert named six stocks you shouldn't overlook—despite Anthropic's IPO

22.10.2026 17:05

Investors seeking safe havens have driven the valuations of "toothpaste" stocks above those of the tech sector

22.10.2026 16:35

Dividends, Gold, ETFs: Wall Street Outlines 5 Steps to Protect Your Portfolio from AI Risks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026